Unlike luminal A/B BC, human epidermal growth receptor 2 (HER2)-positive BC, and basal-like BC, TNBC lacks expression of estrogen receptors (ERs), progesterone receptors (PRs), and HER2, making it unresponsive to hormone therapy, endocrine therapy, and HER2-targeted therapy [2]. This evidence concerns the gene PGR and breast cancer.